CoagulationDisorders near Paramus, NJ

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. William Middlesworth joined the medical staff of Morgan Stanley Children's Hospital of NewYork-Presbyterian/Columbia (MSCHONY), Division of Pediatric Surgery in 1997. He currently serves as director of the Pediatric ECMO Program, and Residency Program Director of the Pediatric Surgical Fellowship. Dr. Middlesworth has founded and leads the Pediatric Thyroid Center and the REACH (Researching Esophageal Atresia for Children's Health) Clinic. A graduate of Dartmouth College, Dr. Middlesworth spent two years in the Genetics Department at the Boston Children's Hospital on work leading to the identification and characterization of the dystrophin gene, important in the pathophysiology of muscular dystrophy. He went on to medical school at Rutgers University, and completed his general surgery training at the University of Maryland Medical System. During residency he spent a year as a surgical research fellow at the Royal Children's Hospital in Melbourne, Australia. His pediatric surgery fellowship was completed at MSCHONY. In addition to the responsibilities listed above, Dr. Middlesworth serves on numerous hospital and university committees focused on Quality and Patient Safety, and is the Quality Chair for Columbia Department of Surgery. He is the Surgeon Champion at the Columbia campus for the National Surgical Quality Improvement Project (NSQIP) of the American College of Surgeons. He chairs a multi-institution collaborative to reduce harm and enhance safety in the peri-operative setting that is sponsored by MCIC Vermont, the member-owned malpractice insurance carrier for Columbia, Cornell, New York Presbyterian Hospital, Johns Hopkins Medicine, University of Rochester Medicine and Yale. Dr. Middlesworth is a fellow of the American College of Surgeons, and the American Academy of Pediatrics. He is a member of numerous professional organizations dedicated to advancing the surgical care of infants and children, including the American Pediatric Surgical Association (APSA), the Eastern Association for the Surgery of Trauma(EAST) and the Extra-corporeal Life Support Organization(ELSO), among others. Dr. Middlesworth has been selected as a Best Doctor in New York Magazine, and a Castle Connolly Top Doctor. He has received recognition for excellence in teaching, and authored numerous papers in important journals including the Journal of Pediatric Surgery, the Journal of Pediatric Hematology and Oncology and Pediatric Critical Care Medicine.

Biography: Monica Bhatia, MD specializes in the care of children with noncancerous blood disorders who may benefit from bone marrow transplantation, especially sickle cell anemia. She and her colleagues are working to reduce the toxicity (side effects) and complications of this treatment without compromising its effectiveness, and to make it available to more patients. The field of pediatric hematology brings with it many intellectual challenges, and bone marrow transplantation in particular is especially dynamic. Dr. Bhatia has the opportunity to provide care for the sickest children, potentially curing their disease. She builds strong relationships with her patients and their families that last for years. It is inspiring for her to see young patients grow up to lead healthy, productive lives. NewYork-Presbyterian/Morgan Stanley Children's Hospital has a robust program for bone marrow transplantation for sickle cell anemia - the only cure for this disease. Dr. Bhatia and her team have witnessed remarkable results among children who are cured with bone marrow transplantation and spared from the potentially life-threatening complications of sickle cell disease. Yet despite the advances made, only 15 percent of patients with sickle cell disease have a matched sibling bone marrow donor. Therefore, Dr. Bhatia and her team conduct research to evaluate a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow for patients without a matched sibling donor. This approach reduces the risk of graft-versus-host disease (GVHD), a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach to harnessing stem cells could potentially make bone marrow transplantation a safer, effective option for many patients who are seeking a cure for sickle cell disease. Dr. Bhatia and her colleagues are currently assessing reduced-intensity transplantation, which uses lower doses of chemotherapy to decrease the risk of side effects and long-term complications without lowering the effectiveness of treatment. She is also interested in looking for ways to further improve the quality of life of patients who have had a bone marrow transplant in addition to fertility preservation.

Biography: Julian Abrams, MD is a Professor of Medicine and Epidemiology at Columbia University Medical Center (CUMC) and Director of Clinical Research for the Division of Digestive and Liver Diseases. He is a specialist in the care of patients with Barrett's esophagus, early esophageal cancer, and other esophageal disorders. His research focus is on risk factors for Barrett's esophagus and esophageal cancer, with a particular focus on the role of the oral and esophageal microbiome as disease biomarkers, promoters of neoplasia, and targets for chemoprevention. He also has conducted extensive outcomes research related to endoscopic therapy for Barrett's esophagus and associated neoplasia.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Karie Runcie, MD is a Hematology Specialist who practices in New York, NY. She is 37 years old and has been practicing for 12 years. Dr. Karie Runcie, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Biography: Dr. Justine Kahn is a Pediatric Oncologist and a clinical investigator specializing in survival outcomes, cancer care delivery, and health equity in children and adolescent/young adults (AYA) with Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Dr. Kahn received her MD from the Icahn School of Medicine at Mount Sinai in New York and completed her Pediatric Residency at Mount Sinai Kravis Children's Hospital in New York. Dr. Kahn completed her Clinical Fellowship in Pediatric Hematology/Oncology at Columbia University Medical Center. While in residency, Dr. Kahn was elected to Alpha Omega Alpha, the national medical honor society which recognizes high educational achievement. During her fellowship, Dr. Kahn served as a Postdoctoral Research Fellow in Cancer-Related Population Sciences supported by the National Cancer Institute for her work in cancer care delivery, health equity, and health outcomes research. Upon graduation from fellowship, Dr. Kahn joined the Pediatric Hematology/Oncology Division at Columbia University Medical Center as an Oncology Instructor and Attending Physician in 2016. She is currently involved in patient care, clinical trials research, and health outcomes research. In June of 2018, Dr. Kahn obtained a Master of Science in Patient Oriented Research at the Columbia Mailman School of Public Health. In July of 2018 she became an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology/Stem Cell Transplantation. Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer. Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma. She serves as CUMC site Principal Investigator for the DFCI ALL Consortium.